Evaluation of the impact of a CoughAssist® mechanical in-exsufflator (MI-E) device on morbidity, quality of life and survival in patients with motor neurone disease (MND) using non-invasive ventilation (NIV)

Submission date	Recruitment status	Prospectively registered
12/05/2010	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
12/05/2010	Completed	[X] Results
Last Edited	Condition category	Individual participant data
13/04/2017	Mental and Behavioural Disorders	

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Muhammad Rafiq

Contact details

Royal Hallamshire Hospital Glossop Road Sheffield United Kingdom S10 2JF

Additional identifiers

Protocol serial number 5372

Study information

Scientific Title

Evaluation of the impact of a CoughAssist® mechanical in-exsufflator (MI-E) device on morbidity, quality of life and survival in patients with motor neurone disease (MND) using non-invasive ventilation (NIV)

Acronym

Evaluating CoughAssist

Study objectives

Without active management of respiratory symptoms, the majority of patients with motor neurone disease (MND) die within approximately 3 - 5 years, from neuromuscular respiratory failure. The applicants have previously shown that non-invasive ventilation (NIV) has a significant positive effect on the quality of life as well as prolonging the survival of MND patients, particularly in patients without severe bulbar dysfunction. However, increasing life expectancy by starting patients on NIV can uncover other downstream problems and a major problem for the patient is the inability to cough effectively. Poor cough can result in chest infections and airway blockage and pulmonary collapse. These problems lead to increasing respiratory failure and often require repeated hospital admissions.

The aim of the present study is to determine whether the use of a mechanical CoughAssist® device can reduce the symptoms of chest infections and therefore hospital admissions whilst improving the quality of life and survival of patients with MND who need to be started on using non-invasive ventilation (NIV). 40 MND patients who require NIV will be assigned to one of two groups via a process of minimisation. One cohort will be assigned to receive NIV and be taught how to use breath-stacking. The other cohort will be assigned to receive NIV and be given the use of a mechanical in-exsufflator (MI-E) (CoughAssist®) machine. Patients will be reviewed every 3 months for 1 year.

Outcome measures include the number of days with symptoms of chest infection, number of days in hospital due to chest infection, quality of life measures, measures of respiratory and neuromuscular function, survival of the patient and the impact of the intervention on the carer. Power calculations are based on the best information available in the literature regarding the number of days of hospitalisation expected for MND patients started on NIV. All outcome measures will be analysed by intention to treat; tests of significance will be two-sided.

Ethics approval required

Old ethics approval format

Ethics approval(s)

MREC approved, ref: 08/H1313/83

Study design

Single-centre randomised interventional prevention, process of care and treatment trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Topic: Dementias and Neurodegenerative Diseases Research Network; Subtopic: Motor neurone disease; Disease: Motor neurone disease

Interventions

CoughAssist® mechanical in-exsufflator versus breath stacking technique.

Study entry: single randomisation only

Intervention Type

Device

Phase

Not Applicable

Primary outcome(s)

Number of days with symptoms of chest infections requiring antibiotic therapy

Key secondary outcome(s))

- 1. Number of days in as a hospital inpatient due to chest infection
- 2. Quality of life (36-item short form health survey [SF-36])

Completion date

01/11/2011

Eligibility

Key inclusion criteria

- 1. The patient should not have any serious medical problems, apart from MND, which may reduce life expectancy
- 2. The patient should be capable of giving informed consent and should not have evidence of any significant impairment of cognitive function
- 3. Patients with MND in respiratory failure meeting two of the following criteria indicating the need for NIV:
- 3.1. Nocturnal or daytime hypercapnia (arterial blood gas [ABG] partial pressure of carbon dioxide in the blood [PaCO2] greater than 6.0 kPa)
- 3.2. Nocturnal hypoxaemia (oxygen saturation [SaO2] less than 88% for 5 consecutive minutes of the time asleep)
- 3.3. Lung function tests forced vital capacity (FVC) less than 60% predicted
- 3.4. Maximal expiratory pressure less than 60 cm H2O
- 3.5. Orthopnoea
- 3.6. Symptoms of hypersomnolence or non-refreshing sleep
- 4. The patient should have a main carer who is willing to assist the patient in following the treatment regimen
- 5. The patient must fulfill the El Escorial clinically or laboratory supported probable or definite criteria for MND

Participant type(s)

Patient

Healthy volunteers allowed

Age group

Adult

Sex

Key exclusion criteria

- 1. Inability to tolerate NIV
- 2. Infringement of the contraindications of CoughAssist® (a history of bullous emphysema, susceptibility to pneumothorax or pneumo-mediastinum, or recent baratrauma)
- 3. Presence of a significant medical condition, other than MND, which may reduce life expectancy
- 4. Presence of significant impairment of cognitive function (for example, clinically overt fronto-temporal dysfunction which is clinically evident and noticeable to the family)
- 5. Participation in any other interventional trial

Date of first enrolment

26/05/2009

Date of final enrolment

01/11/2011

Locations

Countries of recruitment

United Kingdom

England

Study participating centre Royal Hallamshire Hospital Sheffield United Kingdom S10 2JF

Sponsor information

Organisation

Sheffield Teaching Hospitals NHS Trust (UK)

ROR

https://ror.org/018hjpz25

Funder(s)

Funder type

Research organisation

Funder Name

Motor Neurone Disease Association (UK) (ref: shaw/Apr08/6335)

Alternative Name(s)

MND Association, Motor neurone disease (MND), Mndassos, MNDA

Funding Body Type

Private sector organisation

Funding Body Subtype

Associations and societies (private and public)

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/08/2015		Yes	No